GlassScriptPhysician profile
Robin Fritsch
NPI 1356676282
$4,834.75
in general payments reported to CMS, 2019-2025
19 companies · $1,206 in 2025
The $1,206 reported for 2025 was more than what 87% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,024 · 2022: $1,027 · 2023: $632 · 2024: $945 · 2025: $1,206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,783.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,783.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $986.58 | 2022-2025 | Jakafi, Zynyz, Monjuvi |
| E.R. Squibb & Sons, L.L.C. | $663.60 | 2021-2024 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $545.31 | 2021-2025 | Lokelma, Airsupra |
| Alexion Pharmaceuticals, INC. | $331.05 | 2022-2023 | Koselugo, Ultomiris |
| Seagen INC. | $326.49 | 2021 | |
| Janssen Biotech, INC. | $274.94 | 2021-2024 | Rybrevant |
| Exelixis INC. | $249.48 | 2022-2025 | Cabometyx |
| Pfizer INC. | $224.59 | 2022-2025 | |
| Blueprint Medicines Corporation | $124.74 | 2024 | Ayvakit |
| Otsuka America Pharmaceutical, INC. | $124.74 | 2024 | Rexulti |
| Amgen INC. | $124.74 | 2022 | |
| Sanofi-Aventis U.S. LLC | $124.74 | 2025 | |
| Eisai INC. | $124.13 | 2021 | |
| Coloplast Corp | $116.31 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $114.82 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $104.69 | 2024 | |
| Biogen, INC. | $99.86 | 2022 | |
| Esperion Therapeutics, INC. | $99.60 | 2021 | |
| Idorsia Pharmaceuticals US INC | $74.34 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Fritsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.